The influence of prescription opioid use duration and dose on development of treatment resistant depression

Jeffrey F. Scherrer, Joanne Salas, Mark D. Sullivan, F. David Schneider, Kathleen K. Bucholz, Thomas Burroughs, Laurel Copeland, Brian Ahmedani, Patrick J. Lustman

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Long-term prescription opioid use is associated both with new-onset and recurrence of depression. Whether chronic opioid use interferes with depression management has not been reported, therefore we determined whether patients' longer duration of opioid use and higher opioid dose are associated with new-onset treatment resistant depression (TRD) after controlling for confounding from pain and other variables. Data was obtained from Veteran Health Administration (VHA) de-identified patient medical records. We used a retrospective cohort design from 2000–2012. Eligible subjects (n = 6169) were 18–80 years of age, free of cancer and HIV, diagnosed with depression and opioid-free for the 24-month interval prior to the observation period. Duration of a new prescription for opioid analgesic was categorized as 1–30 days, 31–90 days and > 90 days. Morphine-equivalent dose (MED) during follow-up categorized as ≤ 50 mg versus > 50 mg per day. Pain and other sources of confounding were controlled by propensity scores and inverse probability of treatment weighting. Cox proportional hazard models were computed to estimate the association between duration and dose of opioid and onset of TRD. After controlling for confounding by weighting data, opioid use for 31–90 days and for > 90 days, compared to 1–30 days, was significantly associated with new onset TRD (HR = 1.25; 95% CI: 1.09‐1.45 and HR = 1.52; 95% CI: 1.32‐1.74, respectively). MED was not associated with new onset TRD. The risk of developing TRD increased as time spent on opioid analgesics increased. Long-term opioid treatment of chronic pain may interfere with treatment of depression.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalPreventive Medicine
Volume91
DOIs
StatePublished - Oct 1 2016

Fingerprint

Treatment-Resistant Depressive Disorder
Opioid Analgesics
Prescriptions
Depression
Morphine
Veterans Health
Pain
Propensity Score
United States Department of Veterans Affairs
Proportional Hazards Models
Chronic Pain
Medical Records
Therapeutics
Observation
HIV

Keywords

  • Depression
  • Epidemiology
  • Opioids
  • Pain

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

The influence of prescription opioid use duration and dose on development of treatment resistant depression. / Scherrer, Jeffrey F.; Salas, Joanne; Sullivan, Mark D.; Schneider, F. David; Bucholz, Kathleen K.; Burroughs, Thomas; Copeland, Laurel; Ahmedani, Brian; Lustman, Patrick J.

In: Preventive Medicine, Vol. 91, 01.10.2016, p. 110-116.

Research output: Contribution to journalArticle

Scherrer, JF, Salas, J, Sullivan, MD, Schneider, FD, Bucholz, KK, Burroughs, T, Copeland, L, Ahmedani, B & Lustman, PJ 2016, 'The influence of prescription opioid use duration and dose on development of treatment resistant depression', Preventive Medicine, vol. 91, pp. 110-116. https://doi.org/10.1016/j.ypmed.2016.08.003
Scherrer, Jeffrey F. ; Salas, Joanne ; Sullivan, Mark D. ; Schneider, F. David ; Bucholz, Kathleen K. ; Burroughs, Thomas ; Copeland, Laurel ; Ahmedani, Brian ; Lustman, Patrick J. / The influence of prescription opioid use duration and dose on development of treatment resistant depression. In: Preventive Medicine. 2016 ; Vol. 91. pp. 110-116.
@article{6fe58599dcc34d528accc4096d4c8c1b,
title = "The influence of prescription opioid use duration and dose on development of treatment resistant depression",
abstract = "Long-term prescription opioid use is associated both with new-onset and recurrence of depression. Whether chronic opioid use interferes with depression management has not been reported, therefore we determined whether patients' longer duration of opioid use and higher opioid dose are associated with new-onset treatment resistant depression (TRD) after controlling for confounding from pain and other variables. Data was obtained from Veteran Health Administration (VHA) de-identified patient medical records. We used a retrospective cohort design from 2000–2012. Eligible subjects (n = 6169) were 18–80 years of age, free of cancer and HIV, diagnosed with depression and opioid-free for the 24-month interval prior to the observation period. Duration of a new prescription for opioid analgesic was categorized as 1–30 days, 31–90 days and > 90 days. Morphine-equivalent dose (MED) during follow-up categorized as ≤ 50 mg versus > 50 mg per day. Pain and other sources of confounding were controlled by propensity scores and inverse probability of treatment weighting. Cox proportional hazard models were computed to estimate the association between duration and dose of opioid and onset of TRD. After controlling for confounding by weighting data, opioid use for 31–90 days and for > 90 days, compared to 1–30 days, was significantly associated with new onset TRD (HR = 1.25; 95{\%} CI: 1.09‐1.45 and HR = 1.52; 95{\%} CI: 1.32‐1.74, respectively). MED was not associated with new onset TRD. The risk of developing TRD increased as time spent on opioid analgesics increased. Long-term opioid treatment of chronic pain may interfere with treatment of depression.",
keywords = "Depression, Epidemiology, Opioids, Pain",
author = "Scherrer, {Jeffrey F.} and Joanne Salas and Sullivan, {Mark D.} and Schneider, {F. David} and Bucholz, {Kathleen K.} and Thomas Burroughs and Laurel Copeland and Brian Ahmedani and Lustman, {Patrick J.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ypmed.2016.08.003",
language = "English (US)",
volume = "91",
pages = "110--116",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The influence of prescription opioid use duration and dose on development of treatment resistant depression

AU - Scherrer, Jeffrey F.

AU - Salas, Joanne

AU - Sullivan, Mark D.

AU - Schneider, F. David

AU - Bucholz, Kathleen K.

AU - Burroughs, Thomas

AU - Copeland, Laurel

AU - Ahmedani, Brian

AU - Lustman, Patrick J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Long-term prescription opioid use is associated both with new-onset and recurrence of depression. Whether chronic opioid use interferes with depression management has not been reported, therefore we determined whether patients' longer duration of opioid use and higher opioid dose are associated with new-onset treatment resistant depression (TRD) after controlling for confounding from pain and other variables. Data was obtained from Veteran Health Administration (VHA) de-identified patient medical records. We used a retrospective cohort design from 2000–2012. Eligible subjects (n = 6169) were 18–80 years of age, free of cancer and HIV, diagnosed with depression and opioid-free for the 24-month interval prior to the observation period. Duration of a new prescription for opioid analgesic was categorized as 1–30 days, 31–90 days and > 90 days. Morphine-equivalent dose (MED) during follow-up categorized as ≤ 50 mg versus > 50 mg per day. Pain and other sources of confounding were controlled by propensity scores and inverse probability of treatment weighting. Cox proportional hazard models were computed to estimate the association between duration and dose of opioid and onset of TRD. After controlling for confounding by weighting data, opioid use for 31–90 days and for > 90 days, compared to 1–30 days, was significantly associated with new onset TRD (HR = 1.25; 95% CI: 1.09‐1.45 and HR = 1.52; 95% CI: 1.32‐1.74, respectively). MED was not associated with new onset TRD. The risk of developing TRD increased as time spent on opioid analgesics increased. Long-term opioid treatment of chronic pain may interfere with treatment of depression.

AB - Long-term prescription opioid use is associated both with new-onset and recurrence of depression. Whether chronic opioid use interferes with depression management has not been reported, therefore we determined whether patients' longer duration of opioid use and higher opioid dose are associated with new-onset treatment resistant depression (TRD) after controlling for confounding from pain and other variables. Data was obtained from Veteran Health Administration (VHA) de-identified patient medical records. We used a retrospective cohort design from 2000–2012. Eligible subjects (n = 6169) were 18–80 years of age, free of cancer and HIV, diagnosed with depression and opioid-free for the 24-month interval prior to the observation period. Duration of a new prescription for opioid analgesic was categorized as 1–30 days, 31–90 days and > 90 days. Morphine-equivalent dose (MED) during follow-up categorized as ≤ 50 mg versus > 50 mg per day. Pain and other sources of confounding were controlled by propensity scores and inverse probability of treatment weighting. Cox proportional hazard models were computed to estimate the association between duration and dose of opioid and onset of TRD. After controlling for confounding by weighting data, opioid use for 31–90 days and for > 90 days, compared to 1–30 days, was significantly associated with new onset TRD (HR = 1.25; 95% CI: 1.09‐1.45 and HR = 1.52; 95% CI: 1.32‐1.74, respectively). MED was not associated with new onset TRD. The risk of developing TRD increased as time spent on opioid analgesics increased. Long-term opioid treatment of chronic pain may interfere with treatment of depression.

KW - Depression

KW - Epidemiology

KW - Opioids

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=84981743365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981743365&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2016.08.003

DO - 10.1016/j.ypmed.2016.08.003

M3 - Article

C2 - 27497660

AN - SCOPUS:84981743365

VL - 91

SP - 110

EP - 116

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

ER -